Journal article
From risk to fairness.
- Abstract:
-
Kadcyla is a drug that extends the life of breast cancer patients by an average of 6 mo. It also happens to be incredibly expensive. The United Kingdom’s National Health Service sparked controversy when it refused to provide this drug to patients, citing its low cost effectiveness. Cases like this raise the question of how societies should make distributive decisions. Should we maximize utility or should we aim to improve the lives of the least fortunate, even if doing so is costly for everyo...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- National Academy of Sciences Publisher's website
- Journal:
- Proceedings of the National Academy of Sciences Journal website
- Volume:
- 113
- Issue:
- 42
- Pages:
- 11651-11653
- Publication date:
- 2016-10-01
- DOI:
- EISSN:
-
1091-6490
- ISSN:
-
0027-8424
- Source identifiers:
-
655675
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:655675
- UUID:
-
uuid:6d2a4c63-fc96-4eea-858e-456e36b6cc4d
- Local pid:
- pubs:655675
- Deposit date:
- 2017-06-27
Terms of use
- Copyright date:
- 2016
If you are the owner of this record, you can report an update to it here: Report update to this record